Allyx Therapeutics aims to deliver a novel approach to preserve and protect synapses for people living with neurodegenerative diseases.

Allyx Therapeutics

Allyx Therapeutics | 834 followers on LinkedIn. Protecting Synapses and Reversing Neurodegeneration | Allyx Therapeutics is a clinical stage biotechnology company aiming to develop disease modifying therapies for Alzheimer&#39;s and Parkinson&#39;s disease by targeting the underlying cause of synapse dysfunction and loss.

Chief Financial Officer - EvolveImmune Therapeutics

Jennifer Gabler

Another pre-clinical tour de force from our colleagues at Yale School of Medicine demonstrating the effect of our lead drug ALX-001 (BMS-984923) on reversing functional connectivity deficits in an #Alzheimers Disease model. Yale Ventures https://lnkd.in/eZqPqW5x

We are honored to receive this grant from the National Institutes of Health Small Business Innovation Research Program (NIH SBIR) as we continue to advance ALX-001 as a potential first-in-class disease-modifying oral therapy in Alzheimer's disease and Parkinson's disease. https://lnkd.in/eT-4bEEA

Thanks to the Alzheimer's Association® for hosting such an incredible #WalktoEndAlzheimers at Lighthouse Point in New Haven yesterday. We were happy to show our support for the community and remember our goal of helping the patients and families living with this disease. #EndAlz

We are thrilled to announce a significant milestone in our journey to combat #Parkinsons disease, the dosing of our first #PD patient in a Phase 1b 28-day repeat dose clinical study. This marks an important next step in our commitment to developing our innovative therapy, ALX-001, to provide a meaningful impact on the lives of those affected by neurodegenerative diseases. This has been a true collaborative effort with our funding partners at The Michael J. Fox Foundation for Parkinson's Research and the clinical team at the Duke Clinical Research Institute . We also extend our gratitude to the patients, families, and partners who have placed their trust in our mission. Stay tuned for more updates as we continue to advance our research and strive towards a brighter future for Parkinson's disease patients. #Biotech #ClinicalTrials #ParkinsonsDisease #Innovation #Healthcare https://lnkd.in/dq5NQWNd

Another nice feature on our efforts to continue advancing ALX-001 for patients with #Alzheimers Disease. https://lnkd.in/eqNEmmwd

What better timing than during June's #Alzheimer 's & Brain Awareness Month than to announce our first #AD patients began treatment with ALX-001, the latest milestone for our team at Allyx Therapeutics . While there has been great progress with anti-amyloid monoclonal therapies and likely an additional commercial treatment option on the way, Alzheimers's will continue to be a major unmet need with patients and families needing more efficacious, safer, and more convenient treatments. This is just the latest milestone in our journey to develop a better and oral treatment for AD. Thanks to all those supporting Allyx Therapeutics in our journey including our investors and grant funders ( National Institute on Aging (NIA) , Alzheimer's Association® , and The Michael J. Fox Foundation for Parkinson's Research ). An additional special thanks to the patients and their families for their participation and enthusiasm. #ENDALZ https://lnkd.in/edPdEkYP

Proud to be recognized by Senator Murphy as April's "Innovator of the Month" for our work in #Alzheimer 's and #Parkinson 's disease and as an example of the thriving #biotech ecosystem here in Connecticut! https://lnkd.in/gCy9WKNc

Immensely grateful to the The National Institutes of Health and The Michael J. Fox Foundation for Parkinson's Research for their continued support of our ALX-001 program and receiving authorization from the FDA on our latest IND in #parkinsonsdisease . https://lnkd.in/ekPb2_5q

Thanks to the Yale Ventures and Biohaven teams for hosting an excellent event at #jpm2024 . Always an honor to share our story and be part of such a strong Connecticut #biotech ecosystem.

Metric
Company Name	Allyx Therapeutics
Symbol
MSH ID	COM:ALLYXTHERA
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage	Grant
Employee Count
Website	allyxthera.com
LinkedIn	allyx-therapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	88
Web Traffic Growth	1.32
Valuation
Raised Capital	3.30M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ALLY

COM:ALLYXTHERA

Allyx Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue